Intajac 11mg Tablet ER contains Tofacitinib, an oral Janus kinase (JAK) inhibitor indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adult patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). The extended-release formulation allows for once-daily dosing, improving patient compliance. Tofacitinib works by selectively inhibiting JAK enzymes, which play a key role in the signaling pathways involved in the pathogenesis of inflammatory and autoimmune diseases. By modulating the immune response, Intajac helps reduce inflammation, joint damage, and associated symptoms such as pain and swelling. It is essential to evaluate patients for active infections, including tuberculosis, prior to initiating therapy, as Tofacitinib can increase the risk of serious infections. Regular monitoring of blood counts, liver function, and lipid profiles is recommended during treatment. Intajac should be used with caution in patients with a history of malignancy or cardiovascular disease. Concomitant use with other immunosuppressants should be avoided unless under specialist supervision. Patients should be advised to report any signs of infection promptly. Intajac 11mg Tablet ER offers an effective therapeutic option for managing chronic inflammatory conditions when conventional therapies are insufficient.